

March 16, 2023



## Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023

BOSTON and ATLANTA, March 16, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will host a virtual R&D Event on Wednesday, March 22, 2023 at 11:00 am ET.

The virtual event will feature presentations and an interactive Q&A session from the Company's executive leadership team and highlight key clinical updates and upcoming milestones across the Company's neurodegenerative and oncological pipeline. The event will provide an overview of pre-clinical studies that formed the basis for the ongoing Phase 2a '201' trial for the Company's lead candidate, IKT-148009, a potent, selective, brain penetrant c-Abl tyrosine kinase inhibitor. Management will highlight the clinical development strategy for the 201 trial as well as future clinical trials evaluating IKT-148009, including its planned expansion into Multiple System Atrophy (MSA). The Company will round its presentation with the status of IKT-001Pro, a prodrug formulation of imatinib mesylate which is currently being evaluated in a bioequivalence study for Chronic Myelogenous Leukemia.

A live webcast of the Company's event will be available on the "News & Events" in the Investors section of the Company's website at [www.inhibikase.com](http://www.inhibikase.com). A replay of the webcast will be available for 90 days following the presentation.

### **About Inhibikase ([www.inhibikase.com](http://www.inhibikase.com))**

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IKT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IKT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IKT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

### **Social Media Disclaimer**

Investors and others should note that the Company announces material financial information

to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use [Twitter](#), [Facebook](#), [LinkedIn](#) and [YouTube](#) as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

### **Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements, including that results in animal studies may not be replicated in humans. Important factors that could cause actual results to differ materially from those in the forward-looking statements include factors that are delineated in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

### **Contacts:**

#### *Company Contact:*

Milton H. Werner, Ph.D.  
President & CEO  
678-392-3419  
[info@inhibikase.com](mailto:info@inhibikase.com)

#### *Investor Relations:*

Alex Lobo  
SternIR, Inc.  
[alex.lobo@sternir.com](mailto:alex.lobo@sternir.com)

📄 View original content to download multimedia <https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-host-virtual-rd-event-on-march-22-2023-301771858.html>

SOURCE Inhibikase Therapeutics, Inc.